T1D Silver Bullet? Provention Bio Soars On Hopes Teplizumab Is Type 1 Diabetes Game Changer

 
• By Sten Stovall

Shares in Provention Bio were pushed sharply higher on Monday after news that a two-week course of its experimental immunotherapy teplizumab dramatically reduced type 1 diabetes diagnosis rates in people at high risk for the disease.

Game changer
Provention Bio Says Teplizumab Represents a ‘Paradigm Shift’ in T1D Treament • Source: Shutterstock

More from Business

More from Scrip